SCHEMBL2162801

SCHEMBL2162801

COc1cc(Br)c(C(=O)Cl)cc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
KDM4E B2RXH2 3/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
RECQL P46063 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HTT P42858 2/20 0.42
BACE1 P56817 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
ERN1 O75460 1/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX5 P09917 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7970746 0.87 LCK (0.69) LCKFYNKDM4ECYP3A4HSD17B10
SCHEMBL31412873 0.84 LCK (0.76) LCKFYNKDM4ELMNACYP3A4
SCHEMBL2157945 0.84 LCK (0.76) LCKFYNKDM4ELMNACYP3A4
SCHEMBL661672 0.84 HTT (0.56) LCKFYNKDM4ELMNACYP3A4
SCHEMBL24379203 0.82 LCK (0.53) LCKFYNKDM4ELMNACYP3A4
SCHEMBL30210988 0.82 LCK (0.53) LCKFYNKDM4ELMNACYP3A4
SCHEMBL1300913 0.77 HSD17B2 (0.55) LCKFYNLMNACYP3A4HPGD
SCHEMBL12072023 0.76 HTT (0.61) LCKFYNKDM4ELMNACYP3A4
SCHEMBL19361333 0.74 ALOX5 (0.48) LCKFYNERN1ALOX5PTGS2
SCHEMBL17169780 0.74 ALOX5 (0.48) LCKFYNMAPTHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146719-B1 PROCESS FOR MAKING GALANTAMINE SCINOPHARM TAIWAN LTD (TW) 2013-08-14 EP disclosed
US-7985879-B2 reacting a 5-hydroxy-4-methoxy benzoic acid derivative with N-methyl-N-(2-[4-hydroxyphenyl]ethyl)amine, to form N-methyl-N-(2-[4-hydroxyphenyl]ethyl)-5-hydroxy-4-methoxy benzene carboxamide, which is useful as an intermediate in the synthesis of lycoremine SCINOPHARM TAIWAN LTD. (TW) 2011-07-26 US disclosed
CN-101674835-A Process for preparing galanthamine SCINOPHARM TAIWAN LTD 2010-03-17 CN disclosed
EP-2146719-A1 PROCESS FOR MAKING GALANTAMINE ScinoPharm Taiwan, Ltd. (TW) 2010-01-27 EP disclosed
WO-2008127560-A1 PROCESS FOR MAKING GALANTAMINE SCINOPHARM TAIWAN LTD. (TW) 2008-10-23 WO disclosed
US-20080255347-A1 Process for making galantamine SCINOPHARM TAIWAN LTD. 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255347-A1 Process for making galantamine GALR2, GALE, GALR1 LCK 4656/4885FYN 2731/4885KDM4E 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.